Short-term remission induction and conso
β
R. Battista; R. Bassan; A. D'Emilio; P. Dragone; P. Viero; E. Dini; Professor T.
π
Article
π
2006
π
John Wiley and Sons
π
English
β 623 KB
## Abstract One hundred and ninety two adults (median age 44 years) with __de novo__ or secondary (__n__ = 17) acute myelogenous leukemia (AML) were managed with a maximum of six intended courses with adriamycin 25 mg/m^2^/d for three days, plus cytarabine 200 mg/m^2^/d and 6βthioguanine 200 mg/m^2